Vcare 2024 Annual Review
Published Time:
2025-01-27 18:01
Source:
I. Innovative Drug R&D Has Witnessed Multiple Significant Advances
① Vicagrel Capsules (anti-platelet):
China: Preparing NDA submission
US: IND approved by FDA
② VC005 Tablets (next-gen selective JAK1 inhibitor):
Phase III for moderate-severe atopic dermatitis: 1st patient enrolled
Phase III for ankylosing spondylitis: Initiated
③ VC005 Gel (topical JAK1 inhibitor):
Phase II for mild-moderate atopic dermatitis: Initiated
II. Patent Layout for Innovative Drugs
Filed 10 patent applications; Granted 7 patents.
III. Sustained Revenue Growth
2024 revenue: ~RMB 440 million; Contract value: ~RMB 690 million.
IV. Strategic Corporate Development
① Closed Series C+ financing (~RMB 200M); Completed shareholding reform.
② Commenced photovoltaic power project construction.
③ Completed warehouse expansion & lab renovation.
④ Tianshu Pharmaceutical Phase I facility passed final acceptance.
V. Accelerated Group Digitalization
① Completed Phase II: CRM platform & data middleware established.
② Launching Phase III: R&D & production project management systems.
VI. Employee Care Highlights
① Organized 8 cultural events
② Held 12 Happy Hour activities
③ Completed 115 promotions
④ ~70 employees received equity incentives
⑤ Conducted 400+ internal trainings
⑥ Hosted 10+ external expert lectures
VII. Honors & Qualifications
Jiangsu Vcare Honored As: National-Level Specialized, Refined, Unique, and Innovative "Little Giant" Enterprises; Top 100 China Pharma Innovation Seed Enterprises; Jiangsu Listed Sci-Tech Enterprise Cultivation Program; Jiangsu Chemical Innovative Drug Engineering Research Center; Top 500 China Hidden Unicorn Enterprises
Nanjing Vcare Honored As: Top 20 CRO Enterprises in China; Jiangsu Provincial Three-Star Cloud-Adopted Enterprise; Nanjing Engineering Research Center for Synthetic Biology & Flow Chemistry
Related News
08
2024
/
07
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) reported positive results from its Phase II clinical trial of VC005 tablets, a second-generation selective JAK1 inhibitor, for the treatment of ankylosing spondylitis (AS).
View Details
02
2024
/
07
Jiangsu Vcare and Geneseeq Form Strategic Partnership for NTRK Companion Diagnostics
On July 2, 2024, Jiangsu Vcare and Geneseeq signed a strategic cooperation agreement in Nanjing’s Jiangbei New District. The collaboration will focus on the joint development and future commercialization of a companion diagnostic kit for the NTRK inhibitor VC004.
View Details
07
2024
/
06
Jiangsu Vcare Unveils Phase I Clinical Trial Results of TRK Inhibitor VC004 at 2024 ASCO
On June 2, 2024，Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) unveiled the Phase I clinical trial results of its self-developed next-generation TRK inhibitor, VC004, for the treatment of locally advanced/metastatic solid tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
View Details
28
2024
/
04
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced the completion of participants enrollment in its Phase I clinical trial for VC005, a second-generation selective JAK1 inhibitor developed as a topical gel formulation for the treatment of mild-to-moderate atopic dermatitis (AD). The trial included four cohorts of healthy volunteers and three cohorts of patients. The blinded analysis demonstrated promising efficacy and safety profiles for the drug.
View Details
20
2024
/
03
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced the completion of Phase II clinical enrollment for its self-developed second-generation selective JAK1 inhibitor VC005 tablets in the treatment of moderate-to-severe atopic dermatitis (AD). Preliminary blinded analysis from the clinical trial demonstrated promising efficacy and safety profiles for VC005.
View Details
07
2024
/
02
I. Important Progress in Innovative Drug R&D ① Submitted NDA to US FDA for anti-platelet drug Vicagrel: If approved, it may benefit ~27.6M US patients with coronary heart disease/stroke. ② Completed 1st patient enrollment in China’s Phase II trial for anti-resistant TRK inhibitor VC004: Phase I data showed ORR of 80%-90% in NTRK fusion+ solid tumors and DOR up to 24 months. ③ Completed Phase II enrollment for 2nd-gen selective JAK1 inhibitor VC005 in ankylosing spondylitis: Preliminary blinded analysis showed favorable efficacy/safety. Additionally: VC004 gel approved for clinical trials; VC005 gel initiated China Phase I for atopic dermatitis; Multiple preclinical projects advanced in cardio-cerebrovascular, oncology, and autoimmune fields.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn